These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16628667)

  • 21. A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapy.
    Ogata K; Kashiwagi T; Iwahashi J; Hara K; Honda H; Ide T; Kumashiro R; Kohara M; Sata M; Watanabe H; Hamada N
    Arch Virol; 2008; 153(8):1575-9. PubMed ID: 18592133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New hepatitis C therapies.
    Pawlotsky JM
    Semin Liver Dis; 2014 Feb; 34(1):7-8. PubMed ID: 24782253
    [No Abstract]   [Full Text] [Related]  

  • 23. Hepatitis C: a new horizon.
    Chang KM
    Gastroenterology; 2006 Dec; 131(6):1667-8. PubMed ID: 17188957
    [No Abstract]   [Full Text] [Related]  

  • 24. Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Bull L; Martinez L; Reynoso R; Salomon H; Arduino R; Barnett B; Quarleri J
    Intervirology; 2008; 51(4):261-4. PubMed ID: 18824873
    [No Abstract]   [Full Text] [Related]  

  • 25. Tailored treatment for hepatitis C.
    Berg T
    Clin Liver Dis; 2008 Aug; 12(3):507-28, vii-viii. PubMed ID: 18625426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New therapeutic prospects in HCV treatment.
    Almasio PL; Ingrassia D; Vergara B; Filosto S
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):775-9. PubMed ID: 19053890
    [No Abstract]   [Full Text] [Related]  

  • 27. [Advances in research of antiviral agents for hepatitis C].
    Kang FB; Zhao M
    Zhonghua Gan Zang Bing Za Zhi; 2006 Dec; 14(12):933-5. PubMed ID: 17196142
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment choice of the antiviral agent for the hepatitis C].
    Karino Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():269-73. PubMed ID: 26845943
    [No Abstract]   [Full Text] [Related]  

  • 29. Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection.
    Knops E; Heger E; Koenig C; Moebius U; Lübke N; Kaiser R; Di Cristanziano V; Hüsgen L; Kocyigit C; Rupp J; Sierra S
    Clin Microbiol Infect; 2018 Apr; 24(4):440-441. PubMed ID: 29104172
    [No Abstract]   [Full Text] [Related]  

  • 30. Approaches for the development of antiviral compounds: the case of hepatitis C virus.
    Schinazi RF; Coats SJ; Bassit LC; Lennerstrand J; Nettles JH; Hurwitz SJ
    Handb Exp Pharmacol; 2009; (189):25-51. PubMed ID: 19048196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Progress and new challenges in hepatitis C].
    Moradpour D; Frossard JL
    Rev Med Suisse; 2013 Sep; 9(396):1563-4. PubMed ID: 24066462
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
    Cohen J
    Science; 2013 Dec; 342(6164):1302-3. PubMed ID: 24337268
    [No Abstract]   [Full Text] [Related]  

  • 33. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liver biopsy and noninvasive alternatives in relationship to the duration of antiviral treatment for hepatitis C.
    Colletta C; Smirne C; Marini C; Pirisi M
    J Clin Gastroenterol; 2008 Feb; 42(2):219-20. PubMed ID: 18209600
    [No Abstract]   [Full Text] [Related]  

  • 35. Hepatitis C virus host cell interactions uncovered.
    Gottwein JM; Bukh J
    Proc Natl Acad Sci U S A; 2007 Aug; 104(33):13215-6. PubMed ID: 17684095
    [No Abstract]   [Full Text] [Related]  

  • 36. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.
    Mariño Z; van Bömmel F; Forns X; Berg T
    Gut; 2014 Feb; 63(2):207-15. PubMed ID: 24253934
    [No Abstract]   [Full Text] [Related]  

  • 38. Future therapies for hepatitis C.
    Pawlotsky JM; Gish RG
    Antivir Ther; 2006; 11(4):397-408. PubMed ID: 16856613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occult hepatitis C: how convincing are the current data?
    Welker MW; Zeuzem S
    Hepatology; 2009 Feb; 49(2):665-75. PubMed ID: 19105211
    [No Abstract]   [Full Text] [Related]  

  • 40. HCV genotype 5: epidemiology and spread of an uncommon genotype.
    Verbeeck J; Peigue-Lafeuille H; Ross RS; Abergel A; Nevens F; Van der Merwe S; Van Ranst M; Henquell C
    J Clin Virol; 2008 Feb; 41(2):170-1. PubMed ID: 18069057
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.